



Official Title:

SpO<sub>2</sub> Validation of Noninvasive Red Diamond  
Disposable Pulse Oximeter Sensor

Date of Protocol: January 31, 2017

NCT Number: NCT03124602

### Desaturation (Desat)

<b>Protocol/Test Procedure Title</b>	Desaturation (Desat)
<b>Lead Investigator</b>	Tala Harake, MS, BS Clinical Lab Manager Masimo Corporation 52 Discovery, Irvine, CA 92618
<b>Other Investigators</b>	Stacy Lobato, BS Assistant Clinical Lab Manager Masimo Corporation 52 Discovery, Irvine, CA 92618
<b>Expected Start Date</b>	Based on IRB Approval Certification Approval Date
<b>Expected End Date</b>	Based on IRB Approval Certification Expiration Date
<b>IRB</b>	E&I West Coast Board – IRB00007807
<b>Date Submitted To IRB</b>	

#### Protocol Test Abstract:

This document describes a procedure for the evaluation of Masimo SET Pulse Oximeter technology during [REDACTED] hypoxic [REDACTED] conditions. [REDACTED]

[REDACTED] This protocol involves optical data collection and may include placement of venous line(s), arterial line(s), and the collection of invasive reference data.

#### APPROVALS

<b>Author</b>	<b>Date</b>	<b>Engineering</b>	<b>Date</b>
<b>Quality Assurance</b>	<b>Date</b>	<b>Manufacturing</b>	<b>Date</b>

---

**Desaturation (Desat)**

---

This document is a protocol for a clinical research study sponsored by Masimo Corporation. The study will be conducted in compliance with all stipulations of this protocol, the conditions of IRB approval, the Declaration of Helsinki, ISO-14155, applicable regulatory requirements and International Conference on Harmonization Good Clinical Practice guidelines ICH GCP.

**1. PURPOSE**

The objective of this study is to evaluate the performance of Masimo SET® and other pulse oximeters against arterial and/ or venous blood samples analyzed by laboratory analysis on a CO Oximeter [REDACTED]. This will be done in healthy volunteers. [REDACTED]

Desaturation sub studies can be run on numerous parameters or devices while still following this same general procedure. Depending on the specific intent of a particular study, a subset of the procedures described in this protocol may be used [REDACTED]. In addition, volunteer subjects will present with varying tolerance to the desaturation procedure and may not be able to reach the lower saturation levels.

Devices to be used in this study will use Masimo SET technology [REDACTED]. Devices and sensors may be FDA-cleared or investigational. Investigational devices and sensors [REDACTED] products. [REDACTED]

All investigational devices and sensors undergo a risk assessment evaluation prior to use on human subjects to safeguard subjects. No device or sensor that fall under a significant risk device classification as defined in 21 CFR 812.3(m) and determined by the IRB will be used under this protocol.

Pulse oximeters or similar non-invasive devices that are FDA approved or that are investigational may also be tested during this study if needed.

[REDACTED]

Modifications to devices and sensors that [REDACTED] fall outside this protocol and will require a separate IRB application and approval. Procedures and parameters [REDACTED] that fall outside of those identified in this protocol will likewise require a separate IRB application and approval.

**2. BACKGROUND**

Masimo Corporation develops non-invasive medical technologies. These devices have applications in the operating room, critical care unit, emergency room, emergency transport vehicles, alternative (home) care as well as physician's offices.

Masimo SET and Masimo Rainbow technology allows real-time, non-invasive monitoring of oxygen saturation (and other blood solutes) in patients and has the potential to improve clinical outcomes while reducing the cost of care and risks to both patients and clinicians associated with arterial and venous puncture.

---

**Desaturation (Desat)**

---

A problem with current pulse oximeters is that they are not always resistant to patient movement and give either erroneous values, freeze the previous reading, or give a zero reading until the motion ceases.

## 2.1. TECHNOLOGY BACKGROUND

Pulse oximetry is governed by the following principles:

1. Oxyhemoglobin (oxygenated blood) and deoxyhemoglobin (non-oxygenated blood) differ in their absorption of red and infrared light (spectrophotometry).
2. The amount of arterial blood in tissue changes with arterial pulses (photoplethysmography). Therefore, the amount of light absorbed by the varying quantities of arterial blood changes as well.
3. More generally, Masimo Pulse CO-Oximeters use a multi-wavelength sensor to distinguish between not only oxygenated blood and deoxygenated blood, but also blood with carbon monoxide, oxidized blood and blood plasma. The CO-Oximeter utilizes a sensor with various light-emitting diodes (LEDs) that pass light through the site to a photodiode (detector). See figure below.

## 2.2. STUDY DEVICES

Devices used in this study may be either:

- Masimo FDA cleared devices used according to the FDA-approved indication, or
- Masimo investigational devices, which:
  1. Are FDA-cleared devices used outside the FDA approved indication, or



[illegible]

Desaturation (Desat)

[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Desaturation (Desat)

3. REFERENCE

Below is a full list of documents relevant to this protocol and study conduct under this protocol. Please reference this list if additional information is needed on any specifics of this study.

[REDACTED]

[REDACTED]

[REDACTED]

---

Desaturation (Desat)

---

[REDACTED]

**4. LOCATION**

Masimo Corporation  
52 Discovery  
Irvine, CA 92618

(Any other locations will be added by modification)

**5. EQUIPMENT, MATERIALS, AND SAMPLE SIZE JUSTIFICATION****5.1. Safety equipment and Blood Analyzers Maintenance**

- 5.1.1. All blood analyzers, ECG monitors, Blood pressure monitors and safety equipment will be maintained per manufacturer specifications and all study personnel will be trained on the use of relevant equipment.
- 5.1.2. The blood pressure cuff, ECG monitors, and FDA cleared oximeter will be used for monitoring of the participants for their safety.
- 5.1.3. The blood analyzers will be used to run blood samples collected throughout these studies for analyzing blood solutes that are relevant to specific noninvasive technology readings being tested. e.g. Blood will be run for purposes of reading hemoglobin from sample compared to non-invasive hemoglobin reading from Masimo Hemoglobin sensor.

**5.2. Equipment and Materials: to be used as required. All lab analyzers and equipment will be maintained per manufacturer specifications and all study personnel will be trained on the use of relevant equipment.**

Equivalent equipment and materials to those listed below may be used: All lab analyzers and equipment will be maintained per manufacturer specifications and all study personnel will be trained on the use of relevant equipment.

Subject safety monitoring equipment and medical supplies

- Non-invasive blood pressure arm cuff(s)
- ECG monitor – FDA approved product
- Urine hCG pregnancy test -female subjects only
- Standard band aids, needles, syringes, sharps container or other standard medical, wound care equipment and biohazard waste containers necessary to carry out the test procedure
- Standard Emergency equipment and medications will be available in on-site during the study
  - 0.5%-2% lidocaine
  - Ethyl Chloride/Pain Ease
  - Heparin or saline flush solution (as required)- or equivalent

---

**Desaturation (Desat)**

---

FDA-Cleared devices and sensors

[REDACTED]

- Rainbow Sensors
- Conventional Pulse Oximeters
- Conventional Pulse Oximeter Sensors
- Conventional Pulse Oximeter Patient Cables

[REDACTED]

Investigational devices and sensors

[REDACTED]

- Pulse Oximeters
- Pulse Oximeter Sensors
- Pulse Oximeter Patient Cables

[REDACTED]

Warming

[REDACTED]

[REDACTED]

- Blanket
- Hot water bottles
- Heating pads

[REDACTED]

Oxygen administration equipment

[REDACTED]

- Oxygen mask

[REDACTED]

Desaturation equipment and safety equipment

[REDACTED]


- Gas tanks, regulators



Desaturation (Desat)



General lab supplies



- Stopwatch



5.3. Sample Size Justification

- 5.3.1. Sample size justification is not applicable for this protocol. This is a protocol for an IRB study with annual renewal therefore the total number of participants will be with the allowance approved by the IRB and submitted annually for renewal while the study remains active.

5.4. Standard Safety Precautions

- 5.4.1. Subjects will have continuous ECG monitoring throughout the study (may not be recorded/ for monitoring by medical staff).
- 5.4.2. ACLS certified physician will be in attendance (in the study space) throughout the entire procedure, and the study will be completed under their general supervision.
- 5.4.3. Any emergency drug deliveries in the case that a subject loses consciousness or has another emergency arise (standard crash cart medications- atropine, ephedrine etc.) shall be recorded. This individual will be monitored and this information will be recorded and submitted to the IRB if necessary (unanticipated adverse event) and the subject will be given the option to follow up with a local urgent care facility.
- 5.4.4. The volunteer will be monitored (through observation by clinical study staff) throughout the study procedure.
- 5.4.5. An additional pulse oximeter will occasionally be used for the duration of the study to monitor subjects' vital parameters to ensure their safety.
- 5.4.6. All adverse events will be recorded.

6. PROCEDURE



Overview: During this study we will recruit subjects; this will include members of the general public and Masimo employees, to participate in a study that lasts approximately 3 hours. During this study we will be testing the sensors and users in order to make an assessment of our noninvasive devices (listed above). Participants in this study will come in and be seated, review the consent information. They will then be asked if they agree or decline participation in the study. The study



---

**Desaturation (Desat)**

---

may include any subset of the procedures listed below. One or more clinician(s) will place venous line(s) and arterial line(s), and clinical staff will place several sensors on the subject. The subject will be taken to different saturation levels [REDACTED]. Blood samples [REDACTED] will be run on our internal blood analysis equipment ([REDACTED]). This blood sampling will serve the purposes of a comparison tool for the readings that were recorded from the noninvasive devices and sensors.

Saturation and heart rate monitoring will take place throughout the study. During this study subjects may have any of the following done [REDACTED] reference blood sampling from an established arterial line or venous line [REDACTED]. The subject will be re-saturated at the end of the study.

**6.1. RECRUITMENT****6.1.1. Advertisement**

6.1.1.1. Recruitment materials are posted publically in local newspapers, craigslist, schools/universities etc.

**6.1.2. Phone Screening**

6.1.2.1. Once the potential subject sees the recruitment material (ie. advertisement) they contact us to inquire more details about the screening. The recruitment process is taken care of by the designated person(s) who is trained for phone screening/scheduling. Appointments are made once the phone screening process is completed and the person screening the subject determines if they qualify or not for the screening based on inclusion exclusion criteria.

6.1.2.2. Information from the screening will be kept in a database located within the firewall Masimo internal network with user level access control enforced domain log in. Additionally the database is encrypted and password protected. The information is kept to contact subjects for other studies they may qualify for or instances to track subjects who call in and provide false information only to qualify.

**6.2. PRE-ENROLLMENT SCREENING AND EXAM**

6.2.1 Subjects will be asked to provide a copy of their valid government photo ID and/or Social Security (SSN) to verify subject information in our scheduling database and/or to verify the subjects' identity. Foreign persons (A foreign person includes a nonresident alien individual and certain foreign entities that are not U.S. persons) will be asked to provide a copy of U.S. immigration documents/Tax ID Number (TIN) or equivalent, and to complete a W-8BEN form to report earnings to the Internal Revenue Service (IRS).

The copies of these forms of identification will be stored along with the subjects consent documents. The confidentiality and retention of these documents will be protected to the extent provided and required by the law.

The SSN number and ID card is kept to verify subject's identities or instances to track subjects who provide false identification.

6.2.2 Subjects will be informed of the procedure prior to participating in the study. Subjects must read and sign the consent document, using our informed consent process. The consent form must be stamped with a current IRB approval. No study related activities will be conducted until consent is signed.

### Desaturation (Desat)

- 6.2.3 Weight is self-reported by the subject, but if the subject appears to be outside the weight range based on the inclusion/exclusion criteria, subjects will be weighed on a scale.
- 6.2.4 After consenting, subjects will be asked a brief series of health questions to ensure their eligibility for this study. Subjects who do not meet the inclusion and exclusion criteria will not be eligible to participate in the study.
- 6.2.5 Subject demographic information including age, sex, skin tone, ethnicity, height and weight will be collected.
- 6.2.6 In addition, a medical history will be recorded after initial screening questionnaire. Pre-procedural vital signs will be recorded for subject safety monitoring.
- 6.2.7 Female subjects will be required to take a pregnancy test. Results will be noted. If the pregnancy test is positive the subject will be removed from the study and notified of their pregnancy test results.

A venous blood sample will be obtained and analyzed

- 6.2.9 Subjects may have a blanket placed on them (per request of subject or staff).
- 6.2.10 Subjects may be offered a snack (ie. Granola bar) and/or beverage (ie. Water, juice) due to the amount of time their involvement in this study may take.

### 6.3. PRE DESATURATION PROCEDURE

- 6.3.1. The subject will be seated, standing and/or lying in supine position and should refrain from excessive movement during the study.
- 6.3.2. Safety monitors will be placed on the subject, which may include FDA-cleared pulse oximeters, ECG and blood pressure (may not be recorded automatically depending on the protocol, may be recorded manually by medical staff).
  - 6.3.2.1 Post Qualification: Spikes in blood pressure and heart rate can be expected during (but is not limited to) line placement, needle sticks, blood draws etc. and may also be attributed to anxiety/nervousness relating to a new environment. For most participants, only the initial recorded blood pressure and/or heart rate determines a subject's qualification for the continuation of the screening procedure. In the case where heart rate and blood pressure changes suggest participant discomfort or a potential safety concern, the participant will be removed from the study after qualifying. This will be left to the discretion of medical and study staff.

---

**Desaturation (Desat)**

---

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

- 6.3.7 The subjects will be informed of the type of procedure that they will be participating in before enrollment in the study.

[REDACTED]

- 6.3.9 Blood samples will be discarded after testing. These samples will be discarded in the appropriate biohazard waste bins and the samples are de-identified.

- 6.3.10 [REDACTED]

[REDACTED]

#### **6.4. DESATURATION PROCEDURE**

- 6.4.1 This is a general procedure, sensor placement will be based on the testing requirements [REDACTED].

- 6.4.2 Monitors and sensors will be attached to the volunteer ([REDACTED])

[REDACTED]

[REDACTED]

---

Desaturation (Desat)

---

- [REDACTED]
- 6.4.4 Arterial and/ or venous blood samples may be drawn [REDACTED] during the procedure at different saturation levels. [REDACTED]

[REDACTED]

[REDACTED] Upon indication the subject is comfortable, a gas mixture will be administered. The proportion of oxygen in this mixture will be decreased to lower the subject's blood oxygen saturation. [REDACTED]

- 6.4.5.1 Note: At any point in the study, if the subject feels uncomfortable, the subject will be given 100% oxygen.
- [REDACTED]

- 6.4.6 [REDACTED]

- 6.4.6.4 Blood samples may be taken [REDACTED]

- 6.4.7 Subjects may be warmed [REDACTED]

[REDACTED] (for example):

• [REDACTED]

Methods for warming (for example):



---

**Desaturation (Desat)**

---

- Use of a blanket
- Hot water bottles

6.4.8 The study will be ended with several minutes at a FiO2 greater than room air (21%) to help the subject re-saturate after the procedure. If at any point the subject is uncomfortable with the study the study will be stopped.

**6.5. END OF DESATURATION PROCEDURE**

- 6.5.1 The total procedure time will be approximately 180 minutes. In the event that the total procedure time exceeds 180 minutes, subjects will be compensated for the extra time.
- 6.5.2 At the conclusion of the procedure, the sensors/devices, [REDACTED] and arterial line(s) will be removed and the volunteer will be allowed to leave after medical personnel determine it is safe to do so.
- 6.5.3 All volunteers will be encouraged to remain in the study area until they feel fit to leave; subjects should feel safe and able before returning to work directly after participation in the study. Masimo employees will be advised to take as much time as they need after the study before returning to work.
- 6.5.4 Volunteers will be given instructions on wound care. All volunteers will be instructed to contact the principal investigator or study staff in the event of any potential complication.
- 6.5.5 Volunteers will be paid according to the compensation breakdown on the consent form.
- 6.5.6 Subjects will be provided with information related to any significant new findings that develop at any time during the study which may relate to their willingness to continue their participation, their health and/or medical care.

**6.6. TIMING REQUIREMENTS FOR SUBJECT PARTICIPATION**

There are waiting periods associated with different studies and protocols, below is a list of waiting periods for participating in this study.

## Desaturation (Desat)

Circumstances	Wait Period Before Participating
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]

**7. ACCEPTANCE CRITERIA (IF APPLICABLE)**

- 7.1 Acceptance criteria not applicable as this protocol is for data collection purposes for product research and development.

**8. DATA ANALYSIS PROCEDURE TO BE USED**

- 8.1. As this protocol is to collect data for the purposes of product [REDACTED] validation, [REDACTED] a full description of the statistical analysis plan will be provided [REDACTED] prior to subject enrollment [REDACTED].
- 8.2. Sample size and level of significance and power

---

**Desaturation (Desat)**

---

Sample size is non-deterministic and will be determined per [REDACTED] testing set.

8.3. Study Variables

8.3.1. Devices (see section 2 for descriptions and limits)

8.3.2. Procedures (see section 6 for descriptions and limits)

8.3.3. Subjects (see section 9 for descriptions and limits)

8.3.4. Other: None allowed unless named.

8.4. Measures taken to minimize/avoid bias:

8.4.1. Subjects are selected from the population surrounding the test site (including employees). Where applicable, subjects with required demographics (skin color, age, gender, etc.) may be preferentially recruited.

8.4.2. Sensors and devices will be provided to operators in a way that [REDACTED]

8.4.3. Operators will not make any decisions based on results from other operators or any parameters obtained from blood samples.

8.5. Statistical Design

8.5.2. When applicable, [REDACTED]  
will describe any reasons for terminating the study early.

8.6. Data Quality Assurance

8.6.1. The investigator/study staff shall prepare and maintain accurate case histories designed to record all observations and other data pertinent to the study for each study participant. All information shall be recorded on the case report forms.

8.7. Case Report Forms

8.7.1. Data shall be entered into a Case Report Form. The relevant data on the Case Report Forms will be transferred into a database for analysis. No subject identifiers will be collected on the Case Report form. Access to the completed Case Report Forms and Study Database will be password protected and limited to study personnel.

8.7.2. Case report forms will capture protocol deviations and will prompt any notifications to the IRB.

8.8. Expected Dropout Rates

---

**Desaturation (Desat)**

---

There are two possible dropout causes:

8.8.1. The first is if the sensor/device fails to provide a valid reading on a Subject. Depending on desired endpoints and parameter statistics, [REDACTED] may address how many valid measurements are required to include a subject in the analysis. The second is if the Subject does not wish to complete the study. All subjects have the right to terminate the study at any time. Depending on the number of valid measurements taken prior to termination, the sponsor may elect to keep the collected data.

8.8.2. [REDACTED]

## **9. SUBJECTS**

9.1. Potential subjects may be recruited and enrolled according to the criteria below. [REDACTED]

### **Inclusion Criteria (Eligible Subjects)**

- Competent non-smoking (smokers including e-cigarette users) adults between the ages of 18 and 50 years of age.
  - We may also be interested in specifically recruiting smokers for some portions of this study as well as non-smokers for other portions of this study.
- Must weigh a minimum of 110 lbs and no more than 250 lbs unless subject is over 6 feet tall.
- BMI  $\leq 35$
- Must have a hemoglobin value greater than or equal to 11 g/dL.
- Baseline heart rate 45 bpm to 85 bpm.
- CO value  $\leq 2.0\%$  FCOHb (unless we are specifically interested in recruiting smokers)
- Physical status of ASA I or II (American Society of Anesthesiology Class 1; Healthy subjects without any systemic disease at all. American Society of Anesthesiology Class II; subjects with mild systemic disease)
- Blood Pressure (Systolic BP  $\leq 140$  mmHg and Diastolic BP  $\leq 90$  mmHg).
- Able to read and communicate in English
- Has signed written informed consent
- Female, non-pregnant.
- Female subjects will be provided with a pregnancy test free of charge.

### **Exclusion Criteria (Ineligible subjects)**

- Subjects who do not understand the study and the risks involved.
- Subjects with open wounds, lacerations, inflamed tattoos or piercings, visible healing wounds.
- Subjects with frequent or severe headaches and/or migraine headaches.
- Subject has known drug or alcohol abuse. Subjects who uses recreational drugs.
- Subject has experienced a head injury with loss of consciousness within the last year.
- Any chronic bleeding disorders (i.e. hemophilia)
- Any history of a stroke, myocardial infarction, seizures or heart attack.

---

**Desaturation (Desat)**

---

- Any cancer or history of cancer (not including skin cancer).
- Chronic neurological diseases (i.e. multiple sclerosis, Huntington's Disease).
- Any cardiac dysrhythmias (i.e. atrial fibrillation)(without physicians clearance)
- Subject has known neurological and/or psychiatric disorder (i.e. schizophrenia, bipolar disorder) that interferes with the subjects' level of consciousness.
- Known or concurrent chronic usage of psychoactive or anticonvulsive drugs. Subjects with psychiatric conditions or are on psychiatric medications (i.e. tricyclic antidepressants, MAO inhibitors, Lithium, neuroleptics, anxiolytics or antipsychotics, except SSRIs).
- Subject has any medical condition which in the judgment of the investigator and/or medical staff, renders them ineligible for participation in this study, such as Reynauds Syndrome.
- Subject has Wolff-Parkinson-White Syndrome or Stokes-Adams Syndrome
- Inability to tolerate sitting still or maintain minimal movement for up to 90 minutes.
- For studies involving finger sensors: subjects with polished, gel or acrylic nails, skin abnormalities affecting the fingers or arms (such as psoriasis, eczema, angioma, scar tissue, burn, fungal infection), distinct finger edema, substantial skin breakdown damaged and/or finger nail deformities (specific finger will not be used, unless we are specifically testing sensors in use with nail polish, gel, and /or acrylic nails).
- Subjects who have/are currently taking anticoagulant medication.
- Subjects who have had caffeine consumption the day of the study.
- Subjects who have taken pain medication within 24 hours of start of study. Unless minimal preventative dose recommended for adults (discretion of physician).
- Subjects having either signs or history of peripheral ischemia.
- Subjects who have had invasive surgery within the past year- including but not limited to major dental surgery, gallbladder, heart, appendix, major fracture repairs (involving plates/screws), jaw surgery, Urinary tract surgery, plastic surgery, major ENT surgery, joint replacement or gynecological surgeries, heart surgery or thoracic surgery.
- Subjects who have had minor surgery or conditions in the past two months including but not limited to minor foot surgery (bunion), arthroscopic procedure, blood donation, plasma donation, skin biopsy/ procedures, root canal, fractures, eye surgery, and other minor procedures.
- Subjects that have been on antibiotics had congestion, head colds, flu, ear infection, chest congestion will have a 2 week waiting period from the time of finishing medications and must have no more symptoms.
- Subjects with claustrophobia, or anxiety.
- Subjects who have been in severe car accidents or a similar type of accidents will have a 12 month waiting period, from the time of the accident; unless upon further medical history questions the physician determines it does not place the subject in any additional harm, increase their risk, or compromise the subjects' safety.
- Subjects who have had a concussion will have a 12 month waiting period, from the time of the concussion.
- Subjects with chronic unresolved asthma, lung disease or respiratory disease.
- Subjects with allergies to lidocaine, latex, adhesives, or plastic.
- Subjects with heart conditions, Diabetes or hypertension.
- Subjects who have given vaginal delivery will have a 6 month waiting period. Subjects who had a pregnancy terminated, a miscarriage or had a C-section will have a 12 month waiting period.
- Subjects who intend on participating in any heavy lifting, repetitive movement of their wrist (including riding a motorcycle) or exercise (working out, riding a bike, riding a skate board



---

**Desaturation (Desat)**

---

etc.), or any activity that will put additional stress on the wrist within 24 hours following a study involving an arterial blood draw and/or arterial line placement.

- Discretion of investigator/study staff

**10. WITHDRAWAL OF SUBJECTS**

Subjects must be withdrawn under the following circumstances:

10.1. The subject withdraws consent

10.2. Discretion of investigator/study staff

10.2.1. For example (not limited to these examples):

10.2.1.1. The investigator/study staff feel that the subject is too money motivated

10.2.1.2. The investigator/study staff feel that the subject does not fully comprehend and understand the consent form

10.2.1.3. The subject is ill-mannered and/or shows aggressive behavior towards study staff

10.2.1.4. [REDACTED]

10.3. Note: There is set criteria that will be used to determine if the subject qualifies to participate in this study. Based on the discretion of the investigator/study staff and/or the evaluation of the qualifying criteria they may be excluded from this study.

- If the investigator/study staff notices a trend with (not limited to these examples) the subjects' blood pressure fluctuating outside the parameters, their heart rate fluctuating outside the parameters, their need to repetitively void early and/or their inability to remain still for the majority of the study they will be removed from the study and may not be used as a participant in that particular study in the future. We don't want to put the subject in any situation that makes them uncomfortable or may compromise their safety (ie. fidgeting, bladder tolerance, hypertension, inability to stay awake, discomfort with mouthpiece, etc.).

**11. ADVERSE EVENTS**

Adverse event: Any untoward medical occurrence in a subjects, users or other persons, whether or not related to the medical device under study.

Device-related adverse event: Adverse event related to, associated with, or caused by, the use of a medical device under study, including but not limited to events that may have been attributed to the device because of device failure or malfunction, improper or inadequate design, manufacture or user error.

Device deficiency: Inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety or performance. Device deficiencies include malfunctions, use errors and inadequate labeling.

- Device deficiencies will be reported according to department procedures.

Serious adverse event: Adverse event that: a) led to death, b) led to serious deterioration in the health of the subject, that resulted in: (i) a life-threatening illness or injury, (ii) a persistent or significant impairment of a body structure or a body function, (iii) in-patient or prolonged hospitalization, or (iv) medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function, or c) led to fetal distress, fetal death

**Desaturation (Desat)**

or a congenital abnormality or birth defect. NOTE: Planned hospitalization for a pre-existing condition, or a procedure required by the clinical investigational plan, without serious deterioration in health, is not considered a serious adverse event.

All adverse events, including inter-current illnesses will be reported and documented as described below.

**11.1 Adverse Events**

11.1.1 All adverse events that occur during the study shall be recorded on the Case Report Form even if the investigator/study staff assess the adverse event as unlikely to be causally related to the test device or study procedures.

**11.2 Serious Adverse Events**

11.2.1 The investigator/study staff shall promptly report both serious adverse events and unanticipated adverse device effects to the sponsor within 48 hours. All serious adverse events will also be reported to the IRB per IRB reporting requirements.

11.2.2 At the time of discharge from the study, any unresolved serious adverse event(s) will be followed up by the investigator/study staff until the event(s) are resolved, stabilized or the patient is lost to follow-up or the adverse event is otherwise explained. The investigator and/or study staff will also instruct the subject to report any subsequent events occurring in the next 30 days, which the subject or the subject's physician believes might reasonably be regarded as caused by or have a reasonable possibility of being caused by the test device or procedures involved in the study.

**12. MEASURES TAKEN TO PROTECT THE RIGHTS AND WELFARE OF SUBJECTS**

12.1. All subjects will be monitored closely throughout the study. There will be an ACLS certified medical doctor present in the study area throughout the study.

12.2. The following measures will be taken to insure the confidentiality of the subjects:

12.2.1. A code (identification) number for each subject will be kept on file.

12.2.2 Only their corresponding identification number will identify subjects.

12.2.3 Access to identifying documents and data will only be made to the principal investigators in the study and study staff.

12.2.4 The confidentiality and retention of these documents will be protected to the extent provided and required by the law.

12.3 Documents and Database

12.3.1 Documents will be kept [REDACTED] after the specific product/tested for is no longer being made. If destroyed, these documents will be shredded and done by a certified company used for destroying medical and clinical data.

---

**Desaturation (Desat)**

---

**12.3. Vulnerable Populations****12.3.1. Employees are considered to be a vulnerable population**

12.3.1.1. Participation is not a condition of employment. There will be no repercussions in the workplace in the case that the employee refuses to participate in the study or withdraws at any point during the study.

12.3.1.2 Neither supervisors nor superiors will be involved in the recruitment of employees for participation in the study.

**12.3.2. Economically disadvantaged or unemployed and educationally disadvantaged**

12.3.2.1. Reasonable compensation will be provided for economically disadvantaged subjects to eliminate possibility of undue influence due to financial incentive.

12.3.2.2. Educationally disadvantaged subjects will be provided ample time to ask questions and comprehend information

**13. RISKS / DISCOMFORTS**

The studies will be conducted per IRB approved procedures. The study subjects will consist entirely of healthy volunteers. The readings obtained during the study will be recorded but will not be used in patient care, monitoring, or diagnosis.

**13.1. Risks****13.1.1 Risks can be categorized into the following categories:**

- Those associated with the device

[REDACTED]

- Those associated with placement of the arterial line (arterial cannulation)
- Those associated with blood draws

[REDACTED] Those associated with warming [REDACTED]

- Those associated with inflicted knowledge
- Those associated with the lidocaine injection
- Those associated with the lidocaine spray

[REDACTED]

- Those associated with loss of confidentiality/privacy
- Those associated with additional testing

Note: In the very unlikely, worst case, complications from the study may result in death. The study shall be stopped by the subject or study staff long before this would occur.

**13.1.2. Device Risks**

13.1.2.1. The noninvasive devices used in this study are similar in technology and design to some commercially available pulse oximeters and other non-invasive devices and hence have the same risks. Pulse oximeters and

---

**Desaturation (Desat)**

---

other non-invasive devices are commonly used and are considered to be minimal risk.

13.1.2.2. There is an extremely small risk of damage to the subject's fingers, or other locations where sensors are placed, from the device including temporary skin irritation or discomfort associated with exposure to the sensor as well as potential temporary mechanical irritation or discomfort. There is a remote, yet possible, risk of a burn from the sensor. In the case of a sensor burn there is the potential for permanent skin damage (scar/discoloration).

13.1.2.2.1. If there are any cuts and/or abrasions near the finger nail certain types of sensors may not be placed on the particular finger to avoid any discomfort for the subject.

**13.1.3. Venous Cannulation Risks:**

13.1.3.1. Risks associated with venipuncture include bleeding, infection, hematoma, damage to the blood vessel and surrounding nerves or tissue.

13.1.3.2. Discomfort is generally associated with needle puncture. The most common complications associated with blood draws are hematomas or bruising. Other anticipated adverse events that may occur, include but are not limited to:

- Vasovagal (passing out)
- Infiltrated IV
- Lightheadedness
- Feeling flush/warm
- Feeling nauseated
- Throwing up
- Seizures
- Sudden drop in blood pressure/sudden increase in blood pressure
- Sudden drop in heart rate/sudden increase in heart rate
- Tingling sensation of face, arms and/or legs
- Sweating
- Mouth dryness

These anticipated adverse events are expected to be temporary.

**13.1.4. Arterial Cannulation Risks:**

13.1.4.1. The radial artery is the most common site for invasive blood pressure monitoring in anesthesia and critical care medicine because it is technically easy to cannulate and complications are uncommon, in part owing to the good collateral circulation of the hand. The widespread application of invasive arterial pressure monitoring in anesthesia and intensive care is related to the extremely good safety record of this technique.

- Other risks include bleeding, infection, hematoma, damage to the blood vessel and surrounding nerves, tendons or tissue; loss of feeling in hand and/or arm and even the loss of hand due to rare complications of the study.

---

**Desaturation (Desat)**

---

**13.1.5. Blood Draw Risks**

- 13.1.5.1. Discomfort is generally associated with needle puncture. The most common complications associated with blood draws are hematomas or bruising.
- 13.1.5.2. All blood draws will be performed by qualified personnel. An ACLS certified physician will be in attendance throughout the entire procedure, and the study will be completed under their general supervision.
- 13.1.5.3. Other anticipated adverse events that may occur, include but are not limited to:
- Vaso vagal (passing out)
  - Infiltrated IV
  - Lightheadedness
  - Feeling flush/ warm
  - Feeling nauseated
  - Throwing up
  - Seizures
  - Sudden drop in blood pressure/ sudden increase in blood pressure
  - Sudden drop in heart rate/ sudden increase in heart rate
  - Tingling sensation of face, arms and/or legs
  - Sweating
  - Mouth dryness

These anticipated adverse events are expected to be temporary.

**13.1.6. Risk from Low Oxygen Concentration**

- 13.1.6.1. Risks associated with hypoxia include dizziness, shortness of breath, drowsiness, or headache. If or when this occurs, the study can be stopped.
- 13.1.6.2. There is an extremely small risk of loss of consciousness or death from lack of oxygen. The study shall be stopped by the subject or clinical staff long before this could occur.
- 13.1.6.3. Other anticipated adverse events that may occur, include but are not limited to:
- Vaso vagal (passing out/fainting)
  - Lightheadedness
  - Feeling nauseated
  - Throwing up
  - Seizures
  - Sudden drop in blood pressure/ sudden increase in blood pressure
  - Sudden drop in heart rate/ sudden increase in heart rate
  - Tingling sensation of face, arms and/or legs
  - Sweating
  - Mouth dryness

These anticipated adverse events are expected to be temporary.



Desaturation (Desat)

**13.1.7. Risk from Inflicted Knowledge**

13.1.7.1. The risk of inflicted medical knowledge to volunteers is negligible since we deidentify all associated sample information including those relevant to our clinical and engineering parameter studies. The monitoring and test results are not examined for diagnostic purposes and do not reflect an attempt to ascertain any subject's medical condition. The attending physician's role during this study is to ensure the safety of the subject during the study. We will reduce the risk of inflicted knowledge by assuring the subjects that device readings and blood measurements are for research use only. In the case that a subject becomes aware of a condition (anemia, hypertension, arrhythmia etc.) they have during the course of our study our study staff will recommend that they contact their primary care physician and we will document this recommendation. As part of that process we will follow up with these individuals prior to enrollment if their condition meets exclusion for that particular study.

**13.1.8. Lidocaine (injection) risks**

13.1.8.1. Insertion of the Lidocaine may be discomforting and can feel like a slight pinch along with a warm/burning sensation.

13.1.8.2. Other anticipated adverse events that may occur, include but are not limited to:

- Flushing or redness of the skin
- Itching skin
- Small red or purple spots on the skin
- Unusually warm skin
- Bruising
- Bleeding at the application site
- Swelling

These adverse events are expected to be temporary.

Although not common, it is also possible to have an allergic reaction to injectable lidocaine. Subjects should not take part in this study if they are allergic to lidocaine injection or other types of numbing medicine, or if they have a heart rhythm disorder called Wolff-Parkinson-White Syndrome or Stokes-Adams syndrome. Subjects are instructed to tell the study staff right away if they experience hives; difficulty breathing; swelling of their face, lips, tongue or throat.

**13.1.9. Ethyl Chloride (Lidocaine Spray)**

13.1.9.1. Ethyl Chloride is a topical anesthetic which is used to prevent pain by cooling the skin.

13.1.9.2. Although unlikely, the anticipated adverse events that may occur, include but are not limited to:

- Changes in skin color (ie. Flushing or redness of the skin)
- Delayed wound healing

---

Desaturation (Desat)

---

- Rash
- Itching
- Swelling

These adverse events are expected to be temporary.

**Risk from Effects of Warming**

Perfusion to extremities varies amongst individuals as well as throughout the day. It is affected by core body temperature, ambient temperature, cardiac output, vascular tone, medications as well as other factors

13.1.10.2.Changes in temperature may cause temporary changes in heart rate, or premature ventricular contractions (PVC).

13.1.10.5.The most common discomforts associated with warming may include sweating and/or may cause the subject to feel tired. In rare instances skin burns may occur when using heating/warming blankets, in the case that this may occur, the blanket will be removed and our medical staff will determine proper course of action depending on the severity of the burn.

13.1.11.

---

**Desaturation (Desat)**

---

**13.1.12 Risk from Loss of Confidentiality**

- 13.1.12.1 Masimo upholds the highest standards to protect hard and electronic data however a complete promise for confidentiality cannot be guaranteed due to unforeseeable events.

**13.1.13 Risk from Additional Testing**

- 13.1.13.1 During the conduct of the study, it is possible, but not likely, that someone could become exposed to the sample of blood drawn from the subject through an inadvertent needle stick or by contact with an open cut. In such circumstances, it will be important to the exposed individual to know whether the blood to which he or she was exposed contained Hepatitis B virus (HBV), Human immunodeficiency virus (HIV), or Hepatitis C virus (HCV) and additional testing of the sample will be performed.
- 13.1.13.2 Within the consent subjects will agree to permit the company to test the blood sample (or samples) by signing the consent. The test results will be maintained as confidential and will only be used by healthcare professionals for the diagnosis and treatment of the exposed individual as appropriate.
- 13.1.13.3 In the case that Masimo needs to contact a subject regarding additional testing they will be contacted by a Masimo employee and medical personnel can be available for further counsel if requested.
- 13.1.13.4 The cost for the initial testing and compensation for their time/travel to the testing facility will be the only things paid for by Masimo.

**14. EMERGENCY RESPONSE PLAN FOR MEDICAL EMERGENCIES**

- 14.1. The physician and nurse present during the study will be ACLS certified and will respond to any medical emergency involving a volunteer with the ACLS approved protocol for intervention. A crash cart is on site and full emergency services are within 3 miles.

**15. BENEFITS**

- 15.1. There would be no other benefit to the subject.
- 15.2. Other possible benefits would be to society as a whole. Validation of the accuracy of this new device could enable healthcare workers to more appropriately treat potentially life threatening conditions.

**16. ALTERNATIVES**

- 16.1. The alternative is to not participate in the study.

**17. ADDITIONAL**

- 17.1. Device Accountability

- 17.1.1. Device accountability procedure, consistent with [REDACTED] Device Accountability for Clinical Investigations

---

**Desaturation (Desat)**

---

## 17.2. Bibliography

- 17.2.1. Masimo Corporation maintains a current list of publications for all of its products and technologies. In order to view the most current clinical information, please visit the Clinical Evidence portion of the Masimo website at <http://www.masimo.com/cpub/clinical-evidence.htm>

**18. PROTOCOL DEVIATION AND PROCEDURE TO AMEND PROTOCOL**

- 18.1. Modifications to the protocol, informed consent materials, recruitment materials, or any other materials provided to subjects must be reviewed and approved by the IRB in accordance with [REDACTED] Institutional Review Board Procedure prior to implementation.
- 18.2. Deviations from the protocol will be reported in a test report for validation studies and in a Summary Case Report for others.